<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005898</article-id><article-id pub-id-type="pmc">PMC11860418</article-id><article-id pub-id-type="doi">10.3390/vetsci12020138</article-id><article-id pub-id-type="publisher-id">vetsci-12-00138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Feline Calicivirus Infection Manipulates Central Carbon Metabolism</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-4329-2122</contrib-id><name><surname>Zhao</surname><given-names>Guangrong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="fn1-vetsci-12-00138" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Hongwei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00138" ref-type="aff">2</xref><xref rid="fn1-vetsci-12-00138" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Xiu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Chenpei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af3-vetsci-12-00138" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1490-7872</contrib-id><name><surname>Yu</surname><given-names>Xin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="af4-vetsci-12-00138" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5250-9170</contrib-id><name><surname>Jiang</surname><given-names>Linlin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00138" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Cong</surname><given-names>Jingxian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="af4-vetsci-12-00138" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Yuanlong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af5-vetsci-12-00138" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jianlong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00138" ref-type="aff">2</xref><xref rid="af4-vetsci-12-00138" ref-type="aff">4</xref><xref rid="c1-vetsci-12-00138" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xingxiao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00138" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00138" ref-type="aff">2</xref><xref rid="af4-vetsci-12-00138" ref-type="aff">4</xref><xref rid="c1-vetsci-12-00138" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Salvarani</surname><given-names>Felipe M.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Domingues</surname><given-names>Sheyla Farhayldes Souza</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Da Silveira</surname><given-names>J&#x000fa;lia Ang&#x000e9;lica Gon&#x000e7;alves</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00138"><label>1</label>School of Life Sciences, Ludong University, Yantai 264025, China</aff><aff id="af2-vetsci-12-00138"><label>2</label>Collaborative Innovation Center for the Pet Infectious Diseases and Public Health in the Middle and Lower Stream Regions of the Yellow River, Yantai 264025, China</aff><aff id="af3-vetsci-12-00138"><label>3</label>School of Basic Medical Sciences, Heze Medical College, Heze 274000, China</aff><aff id="af4-vetsci-12-00138"><label>4</label>Shandong Engineering Research Center for Aquaculture Environment Control, Yantai 264025, China</aff><aff id="af5-vetsci-12-00138"><label>5</label>Shandong Huanong Biopharmaceutical Co., Ltd., Weifang 262600, China</aff><author-notes><corresp id="c1-vetsci-12-00138"><label>*</label>Correspondence: <email>zhangjianlong@ldu.edu.cn</email> (J.Z.); <email>zhangxingxiao@ldu.edu.cn</email> (X.Z.)</corresp><fn id="fn1-vetsci-12-00138"><label>&#x02020;</label><p>These authors contributed equally to the work.</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>138</elocation-id><history><date date-type="received"><day>05</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>03</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>Viruses, functioning as cellular parasites, exhibit a life cycle and metabolic processes that are intricately linked to those of their host organisms. Current investigations have revealed that viruses subvert the metabolic activities of host cells to facilitate their replication. In this study, we employed metabolomic and transcriptomic sequencing techniques to establish that FCV023 infection in CRFK cells elicits a pronounced shift in the host&#x02019;s central carbon metabolism, with FCV023 demonstrating a distinctive pattern of carbon utilization. The replication of FCV023 was significantly impeded by the application of metabolic inhibitors targeting glycolysis, the pentose phosphate pathway, and glutamine metabolism. Comparative supplementation assays with glutamine and glucose revealed that both are essential carbon sources for optimal viral replication. However, glutamine appears to function as a novel energy substrate within FCV-infected cells, whereas glucose is predominantly channeled into the pentose phosphate pathway to synthesize nucleotides critical for the replication of the viral genome.</p></abstract><abstract><title>Abstract</title><p>Viruses can manipulate the host metabolism to achieve optimal replication conditions, and central carbon metabolism (CCM) pathways are often crucial in determining viral infections. Feline calicivirus (FCV), a diminutive RNA viral agent, induces upper respiratory tract infections in feline hosts, with highly pathogenic strains capable of precipitating systemic infections and subsequent host cell necrosis, thereby presenting a formidable challenge to feline survival and protection. However, the relationship between FCV and host cell central carbon metabolism (CCM) remains unclear, and the precise pathogenic mechanisms of FCV are yet to be elucidated. Upon FCV infection of Crandell-Rees Feline Kidney (CRFK) cells, an enhanced cellular uptake of glucose and glutamine was observed. Metabolomics analyses disclosed pronounced alterations in the central carbon metabolism of the infected cells. FCV infection was found to augment glycolytic activity while sustaining the tricarboxylic acid (TCA) cycle flux, with cellular ATP levels remaining invariant. Concurrently, both glutamine metabolism and the flux of the pentose phosphate pathway (PPP) were noted to be intensified. The application of various inhibitory agents targeting glycolysis, glutamine metabolism, and the PPP resulted in a significant suppression of FCV proliferation. Experiments involving glucose and glutamine deprivation demonstrated that the absence of either nutrient markedly curtailed FCV replication. Collectively, these findings suggest a critical interplay between central carbon metabolism and FCV proliferation. FCV infection stimulates CRFK cells to augment glucose and glutamine uptake, thereby supplying the necessary metabolic substrates and energy for viral replication. During the infection, glutamine emerges as the primary energy substrate, ensuring ATP production and energy homeostasis, while glucose is predominantly channeled into the pentose phosphate pathway to facilitate nucleotide synthesis.</p></abstract><kwd-group><kwd>glycolysis</kwd><kwd>pentose phosphate pathway</kwd><kwd>glutamine metabolism</kwd><kwd>metabolomics</kwd></kwd-group><funding-group><award-group><funding-source>Young Scientists Fund of Shandong Provincial Natural Science Foundation</funding-source><award-id>ZR2024QC103</award-id><award-id>ZR2021QC167</award-id><award-id>ZR2023MC049</award-id><award-id>ZR2024MC148</award-id></award-group><award-group><funding-source>Yantai International science and technology cooperation project</funding-source><award-id>2023YTKXGH006</award-id></award-group><award-group><funding-source>Key Research and Development Plan of Shandong Province</funding-source><award-id>2022CXPT022</award-id></award-group><award-group><funding-source>Shandong Province Poultry Industry Technology System</funding-source><award-id>SDAIT-11-10</award-id></award-group><award-group><funding-source>Bureau of Education of Yantai City, China</funding-source></award-group><funding-statement>This research was funded by the project supported by the Young Scientists Fund of Shandong Provincial Natural Science Foundation (No. ZR2024QC103, ZR2021QC167, ZR2023MC049, and ZR2024MC148), the Yantai International science and technology cooperation project (No. 2023YTKXGH006), the Key Research and Development Plan of Shandong Province (2022CXPT022), the Shandong Province Poultry Industry Technology System (SDAIT-11-10), and the Universities-Industry Collaboration Program funded by the Bureau of Education of Yantai City, China (Development of Next-Generation Vaccines Platform for Pet Animals).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00138"><title>1. Introduction</title><p>Feline calicivirus (FCV) is a highly contagious pathogen and a single-stranded positive-sense RNA virus belonging to the Vesivirus genus of the Caliciviridae family [<xref rid="B1-vetsci-12-00138" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00138" ref-type="bibr">2</xref>]. FCV exhibits a broad host range within the Felidae family, infecting all recognized members such as leopards, lions, and tigers. Additionally, there have been documented instances of FCV isolation in canines. This potential for cross-species infectivity and transmissibility presents substantial threats to the viability of both wild and domestic felids. Infection with FCV can induce a spectrum of clinical manifestations in the host, including pyrexia, ulceration, tracheitis, and other upper respiratory tract symptoms. Notably, the virulent systemic variant of feline calicivirus (VS-FCV) is capable of inducing systemic infections and may ultimately result in host lethality [<xref rid="B3-vetsci-12-00138" ref-type="bibr">3</xref>,<xref rid="B4-vetsci-12-00138" ref-type="bibr">4</xref>]. FCV is currently endemic worldwide, yet the pathogenic mechanisms of FCV remain unclear. The protective efficacy of existing vaccines against FCV is limited, and there are no specific antiviral drugs available for clinical treatment. Therefore, elucidating the pathogenic mechanisms of FCV is urgent for the development of targeted drugs and the design of novel vaccines, which is of great significance for the prevention, control, and treatment of FCV [<xref rid="B5-vetsci-12-00138" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-12-00138" ref-type="bibr">6</xref>].</p><p>CCM functions as a pivotal metabolic pathway in organisms, facilitating the acquisition of energy. It enables the swift provision of energy and serves as a source of metabolic precursors essential for the biosynthesis of lipids, amino acids, and a variety of other biomolecules. Consequently, central carbon metabolism has become a key metabolic process that viruses target and reprogram after infecting host cells. As obligate intracellular parasites, viruses require the hijacking of the host cell&#x02019;s metabolic network to complete their own replication [<xref rid="B7-vetsci-12-00138" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-12-00138" ref-type="bibr">8</xref>]. In order to secure a competitive edge for survival, viruses actively reprogram and co-opt the host&#x02019;s metabolic pathways to optimize their replication. A prevalent mode of cellular subversion employed by viruses involves the alteration of the host cell&#x02019;s glycolytic flux, culminating in the Warburg phenomenon. This is typified by an augmented rate of anaerobic glycolysis within the cellular milieu. The Warburg effect is not merely an enhancement of glycolytic activity; it is typically accompanied by an increase in glutaminolysis, the metabolic breakdown of glutamine [<xref rid="B9-vetsci-12-00138" ref-type="bibr">9</xref>]. In summary, viral molecules promote viral replication by inducing metabolic reprogramming in the host, and studying the connection between viral infection and host metabolism is a new direction for the development of antiviral drugs and diagnostic reagents. Targeting immune cell functions through metabolic modulation is a promising avenue for future immunotherapy [<xref rid="B10-vetsci-12-00138" ref-type="bibr">10</xref>].</p><p>Viral infections often accompany the reshaping of the host&#x02019;s metabolism, with changes in carbon metabolism being the most common. However, the impact of FCV infection on host cell metabolism has not yet been studied. In order to further elucidate the role of host cell metabolism in the proliferation of FCV and to preliminarily explore the potential mechanisms by which FCV induces metabolic reprogramming in host cells, we employed unbiased metabolomic and transcriptomic sequencing to detect changes in central carbon metabolism-related metabolites and gene expression in FCV-infected CRFK cells. The results indicate that the infected cells increased their uptake of glucose and glutamine, with significant and concentrated changes in the abundance of central carbon metabolism and related products, indicating a reshaping of the central carbon metabolic pathway. The use of metabolic blocking drugs to block glycolysis, the pentose phosphate pathway, and glutamine metabolism effectively inhibited FCV replication in CRFK cells. Glutamine and glucose depletion experiments proved that both glutamine and glucose are essential for FCV proliferation. In summary, FCV infection reshapes the central carbon metabolic characteristics of CRFK cells to meet its own replication needs. Hence, targeting CCM may represent an innovative metabolic therapeutic target for FCV, facilitating the development of anti-FCV infection drugs.</p></sec><sec id="sec2-vetsci-12-00138"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00138"><title>2.1. Cell Culture and Viral Infection</title><p>CRFK cells were purchased from Wuhan Pricella Biotechnology (Wuhan, China). CRFK cells were cultured in DMEM (Wuhan, China) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37 &#x000b0;C in a humidified 5% CO<sub>2</sub> incubator. The FCV023 strain is isolated and preserved by our laboratory (GenBank: PP112969).</p></sec><sec id="sec2dot2-vetsci-12-00138"><title>2.2. Reagents</title><p>DMEM was purchased from Wuhan Pricella Bio-technology(Wuhan, China). 2-Dexoy-D-Glucose (2-DG), Sodium Oxamate, 6-Aminonicotinamide (6-AN), CB-839, were obtained from Topscience (Shanghai, China) and diluted in accordance with the instruction. Monoclonal antibodies targeting the FCV VP1 protein were purchased from Absolute Antibody in the USA. Goat anti-rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor488, and Actin Muscle Monoclo-nal Antibody were purchased from Invitrogen (Carlsbad, CA, USA).</p></sec><sec id="sec2dot3-vetsci-12-00138"><title>2.3. RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction</title><p>Total RNA from cells was extracted with TRizol (St. Louis, MO, USA) and used as the template for reverse transcription. cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Waltham, MA, USA). q-PCR experiments were carried out using AceQ qPCR Probe Master Mix and AceQ qPCR SYBR Green Master Mix (Nanjing, China) according to the manufacturer&#x02019;s instructions to measure transcripts or FCV RNA levels. The level of mRNA expression was normalized with &#x003b2;-actin. The sequences of primers are listed in (<xref rid="vetsci-12-00138-t001" ref-type="table">Table 1</xref>), and the qPCR reaction protocol is shown in <xref rid="vetsci-12-00138-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot4-vetsci-12-00138"><title>2.4. Western Blotting Assay</title><p>Cells were lysed with RIPA Lysis and Extraction Buffer (Waltham, MA, USA) containing PMSF (Waltham, MA, USA) protease inhibitor. The titer of total protein was quantified using Protein Reagent Assay BCA Kit (Waltham, MA, USA). Western blot analysis was carried out according to the standard method. Antibodies used in this research were as follows: rabbit anti-FCV VP1 (Wilton Centre, UK) at a ratio of 1:2000; rabbit anti-&#x003b2;-actin (Waltham, MA, USA) at a ratio of 1:2000 [<xref rid="B11-vetsci-12-00138" ref-type="bibr">11</xref>].</p></sec><sec id="sec2dot5-vetsci-12-00138"><title>2.5. The 50% Tissue Culture Infectious Dose (TCID<sub>50</sub>) Assay</title><p>The Reed-Muench method was used to determine the titer of FCV. CRFK cells were seeded into a 96-well plate. Subsequently, the FCV viral solution was serially diluted by a factor of 10 and used to infect the cells, with each dilution having 8 replicates. After a 72 h incubation period, the number of wells exhibiting cytopathic effects (CPEs) was recorded, and the viral titer was calculated [<xref rid="B12-vetsci-12-00138" ref-type="bibr">12</xref>].</p></sec><sec id="sec2dot6-vetsci-12-00138"><title>2.6. Metabolite Extraction and LC-MS Analysis</title><p>Six biological replicates in FCV or mock-infected CRFK cells were set up for metabolomics detection. Extraction of metabolites and LC-MS analysis were carried out by Majorbio (Shanghai, China). The metabolites with variable importance in the projection (VIP) &#x02265; 1 and <italic toggle="yes">p</italic>-value of &#x0003c; 0.05 according to Student&#x02019;s <italic toggle="yes">t</italic>-test were considered as significantly changed [<xref rid="B13-vetsci-12-00138" ref-type="bibr">13</xref>]. This part of the detection process was completed at Shanghai Megi Biopharmaceutical Technology Co., Ltd. (Shanghai, China).</p></sec><sec id="sec2dot7-vetsci-12-00138"><title>2.7. Cell Viability Assay</title><p>CRFK cells were seeded into 96-well plates at a density of 1 &#x000d7; 10<sup>4</sup>/well and incubated with DMEM containing 10% FBS overnight. Cell culture medium was then replaced with 2% FBS DMEM with different concentrations of inhibitors and incubated for 8 h. Then, 10 &#x003bc;L of Cell Counting Kit-8 (Beijing, China) solution was added to each well and incubated for 4 h. The absorbance of each well was measured at 450 nm using a microplate reader (Revolution Optics, LLC, Burlington , VT, USA). All experiments were performed in quintuplicate.</p></sec><sec id="sec2dot8-vetsci-12-00138"><title>2.8. Statistical Analysis</title><p>Except for special statistical analysis of transcriptome and metabolome described above, other statistical analyses were carried out using GraphPad Prism version 9 (GraphPad Software Inc., La Jolla, CA, USA). Statistical comparisons were carried out using Student&#x02019;s <italic toggle="yes">t</italic>-test. <italic toggle="yes">p</italic>-values &#x0003c; 0.05 were considered significant (* <italic toggle="yes">p</italic> &#x0003c; 0.05,** <italic toggle="yes">p</italic> &#x0003c; 0.01, and *** <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00138"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00138"><title>3.1. FCV023 Isolation Identification and One-Step Growth Curve Determination</title><p>FCV023 was inoculated into CRFK cells, and cytopathic effects (CPEs) were observed at 4 h post-inoculation. The affected cells exhibited pyknosis and detachment (<xref rid="vetsci-12-00138-f001" ref-type="fig">Figure 1</xref>A). Viral supernatants were harvested and subjected to a Western blot analysis and immunofluorescence assay (IFA) using FCV-specific monoclonal antibodies, which detected a protein band of approximately 62 kDa corresponding to the VP1 capsid protein and revealed FCV-specific fluorescent signals (<xref rid="vetsci-12-00138-f001" ref-type="fig">Figure 1</xref>B,C). Transmission electron microscopy (TEM) was employed to visualize the viral particles. As depicted in <xref rid="vetsci-12-00138-f001" ref-type="fig">Figure 1</xref>D, non-enveloped calicivirus-like particles with a characteristic cup-shaped morphology were observed, consistent with the structural features of caliciviruses, confirming the replication and proliferation of FCV023 in CRFK cells.</p><p>The titration of the FCV023 virus was performed using the Reed-Muench method. FCV023 was inoculated into CEFK cells at a multiplicity of infection (MOI) of 1, with culture supernatants collected at 4 h intervals for virus titer (TCID<sub>50</sub>) determination. The virus titer of FCV023 peaked at 8 h post-infection with CRFK cells, remained stable with no significant changes from 8 to 12 h post-infection, and then gradually declined after 16 h of cultivation (<xref rid="vetsci-12-00138-f001" ref-type="fig">Figure 1</xref>E).</p></sec><sec id="sec3dot2-vetsci-12-00138"><title>3.2. Metabolomic Studies Have Identified That FCV023 Infection Affects Central Carbon Metabolism in CRFK Cells</title><p>Metabolomic analyses were conducted on CRFK cells infected with FCV023 at 4, 8, and 12 h post-infection. The results reveal that during FCV infection, the central carbon metabolism in CRFK cells underwent significant reorganization, with notable alterations in the abundance of numerous metabolites within the central carbon metabolic pathways. In the early phase of FCV infection, compared to the mock-infected controls, the levels of glycolytic intermediates, such as pyruvate, 3-phosphoglycerate, and fructose-6-phosphate, were downregulated, while the abundance of the end product lactate was upregulated. The content of glucose-6-phosphate was significantly elevated, and there were marked increases in the abundance of metabolites such as ribulose-5-phosphate and ribose-5-phosphate, indicating an upregulation of the pentose phosphate pathway flux. Additionally, the levels of &#x003b1;-ketoglutarate in CRFK cells infected with FCV023 were significantly increased, coinciding with the enhanced metabolism of glutamate and glutamine, with a significant upregulation of related metabolite levels in infected cells. However, the intracellular ATP levels in infected cells remained unchanged compared to those in the uninfected cells (<xref rid="vetsci-12-00138-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot3-vetsci-12-00138"><title>3.3. 2-DG and Sodium Oxamate Reduces FCV023 Infection in CRFK Cell</title><p>Metabolic and transcriptomic analyses of CRFK cells infected with FCV023 indicate that during viral infection, anaerobic glycolysis and PPP flux are increased, while the acetyl-CoA levels are significantly decreased, and the intracellular ATP levels are slightly upregulated. This suggests that the total amount of acetyl-CoA generated from glucose metabolism entering the TCA cycle is downregulated, and other energy metabolic substrates maintain the cellular energy supply. To further determine the role of each central carbon metabolic segment in FCV infection and whether glycolysis favors the replication and proliferation of FCV, CRFK cells were treated with glycolysis inhibitors 2-DG and Sodium Oxamate and then infected with FCV023, followed by the detection of viral genome copies and the production of progeny virus.</p><p>The treatment of CRFK cells with 10 mM of 2-DG or 10 mM of Sodium Oxamate for 8 h did not inhibit CRFK cell activity (<xref rid="vetsci-12-00138-f003" ref-type="fig">Figure 3</xref>A), but after 24 h, it reduced the viability of CRFK cells by approximately 28% and 30% (<xref rid="app1-vetsci-12-00138" ref-type="app">Figure S1</xref>), respectively. Cells were infected with FCV023 at an MOI of 1 for 1 h. After infection, the culture medium containing 10 mM of 2DG or 10 mM of Sodium Oxamate was added to exclude the direct impact of the compounds on viral particles. After an 8 h incubation period, plaque assays observed a significant reduction in the number of infectious viral particles in cells treated with 2DG and Sodium Oxamate, a significant downregulation in viral genome copy numbers, and a significant inhibition of FCV023 capsid protein expression due to the blockade of the glycolytic pathway (<xref rid="vetsci-12-00138-f003" ref-type="fig">Figure 3</xref>B&#x02013;D).</p></sec><sec id="sec3dot4-vetsci-12-00138"><title>3.4. FCV023 Infection Enhances the PPP in CRFK Cells, and the Unobstructed PP Facilitates FCV Infection</title><p>In general, PPP is the major branch pathway used by glycolysis for the de novo synthesis of nucleotides. Nucleotide metabolism plays a crucial role in viral replication, and we utilized a PPP inhibitor, 6-aminonicotinamide (6-AN), to ascertain the impact of the PPP on FCV virus infection. Cultured CRFK cells infected with FCV were treated with a final concentration of 1 &#x003bc;M of 6-AN, which demonstrated significant inhibitory effects on the viral genome level (<xref rid="vetsci-12-00138-f004" ref-type="fig">Figure 4</xref>C), the release of infectious viral particles (<xref rid="vetsci-12-00138-f004" ref-type="fig">Figure 4</xref>D), and the expression of capsid proteins (<xref rid="vetsci-12-00138-f004" ref-type="fig">Figure 4</xref>E,F). This is likely due to the inhibitory effect of 6-AN on nucleotide synthesis, reducing the nucleotide precursors required for viral genome replication.</p></sec><sec id="sec3dot5-vetsci-12-00138"><title>3.5. Glutamine Metabolism Is Crucial for the Proliferation of FCV023</title><p>Glutamine metabolism is crucial for FCV023 infection as it serves as a secondary carbon source when glucose is scarce. It provides the necessary precursors for nucleotide synthesis, which are critical for viral genome replication. The metabolic intermediates of glutamine also support the TCA cycle, aiding in the maintenance of cellular energy supply. Furthermore, glutamine-derived carbon can be used for biosynthetic pathways, ensuring the normal metabolic functions of the cell. Subsequently, at 8 h post-infection, viral genome copies, capsid protein expression, and viral titers were assessed. In CRFK cells, the incubation of CRFK cells with a final concentration of 0.2 mM of CB-839 significantly inhibited the replication and copy of the FCV viral genome (<xref rid="vetsci-12-00138-f005" ref-type="fig">Figure 5</xref>C), reducing the release of infectious viral particles (<xref rid="vetsci-12-00138-f005" ref-type="fig">Figure 5</xref>D) and protein expression (<xref rid="vetsci-12-00138-f005" ref-type="fig">Figure 5</xref>E,F).</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00138"><title>4. Discussion</title><p>Viruses, as obligate intracellular parasites, rely on hijacking the host cell&#x02019;s metabolic network to facilitate their replication. To establish a survival advantage, viruses actively modulate and exploit the host&#x02019;s metabolic pathways to maximize their proliferation [<xref rid="B14-vetsci-12-00138" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00138" ref-type="bibr">15</xref>]. A common tactic employed by viruses is to stimulate glycolysis in host cells, leading to the Warburg effect, characterized by enhanced anaerobic glycolysis. The Warburg effect is not merely an amplification of glycolysis; it often involves intensified glutaminolysis. Central carbon metabolism, the means by which organisms derive energy, can rapidly supply energy and provide metabolic precursors for the synthesis of lipids, amino acids, and other biomolecules [<xref rid="B16-vetsci-12-00138" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-12-00138" ref-type="bibr">17</xref>]. Consequently, central carbon metabolism becomes a focal point for hijacking and reprogramming by viruses following the infection of host cells. Viral infections lead to metabolic remodeling that promotes viral survival and replication, modulates the biological functions of host cells, and determines cell fate. Therefore, exploring the relationship between viral infections and host cell metabolism is a new hotspot in the study of viral infection mechanisms and the development of antiviral drugs [<xref rid="B18-vetsci-12-00138" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-12-00138" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-12-00138" ref-type="bibr">20</xref>].</p><p>Targeting host metabolic pathways has emerged as a novel strategy for developing antiviral drugs, elucidating the mechanisms of viral infection and pathogenesis, and guiding vaccine design [<xref rid="B21-vetsci-12-00138" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-12-00138" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-12-00138" ref-type="bibr">23</xref>]. Currently, the prevention of feline calicivirus (FCV) mainly relies on vaccination. However, the high variability of the virus limits the effectiveness of vaccine-induced immune protection, and there are no effective therapeutic drugs available in clinical settings. In this study, we found that central carbon metabolism underwent significant metabolic reprogramming in FCV-infected CRFK cells, which may be closely related to FCV&#x02019;s immune evasion and proliferation. This suggests that the central carbon metabolism pathway can be a novel drug target for combating feline calicivirus. In this study, the optimal infection time for FCV in CRFK cells was determined to be 8 h post-infection (hpi). During the single-step growth curve determination of FCV023, it was observed that CRFK cells exhibited cytopathic effects 4 h post-infection and reached peak viral titers 8 h post-infection, and almost all cells detached and died by 12 h post-infection. This indicates that FCV023 strongly remodels the host&#x02019;s metabolic activity early in infection to complete its own replication. Therefore, cells were chosen for metabolomic sequencing 8 h post-infection when cell viability was relatively high and viral replication was sufficient.</p><p>Utilizing metabolomic sequencing, we identified unique carbon metabolic changes in CRFK cells during FCV023 infection. Infected cells exhibited a significant reorganization of central carbon metabolism, with a substantial upregulation of lactate levels, indicating an intensification of anaerobic glycolysis in CRFK cells post FCV023 infection. Additionally, there was a slight increase in the overall intracellular energy levels, with a marked elevation of &#x003b1;-KG within the TCA cycle, and enhanced glutamine metabolism emerged as the primary substrate for energy metabolism. Metabolites and gene expression associated with the PPP also showed a significant increase in infected cells; these phenomena were also observed in RAW264.7 cells infected with murine norovirus [<xref rid="B24-vetsci-12-00138" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00138" ref-type="bibr">25</xref>]. In summary, FCV023 infection induces a unique carbon utilization pathway in CRFK cells, with the infection being closely linked to central carbon metabolic processes.</p><p>Hexokinase catalyzes the conversion of glucose to glucose-6-phosphate, serving as a pivotal substrate for various carbon metabolic pathways, thereby influencing multiple aspects of carbon metabolism. In normal cellular metabolism, glucose-6-phosphate is metabolized through glycolysis to produce pyruvate, which can then be converted into lactate or acetyl-CoA, entering the TCA cycle. 2-DG, a glucose analog, acts as a competitive inhibitor of hexokinase, effectively suppressing CCM. However, recent studies have employed 2-DG as an inhibitor of glycolysis, a usage that warrants further consideration [<xref rid="B25-vetsci-12-00138" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-12-00138" ref-type="bibr">26</xref>]. Given its inhibitory target, 2-DG should be considered an inhibitor of CCM. To verify the role of glycolysis in FCV023 infection, Sodium Oxamate was also used to inhibit lactate production, further analyzing the impact of glycolytic pathway blockade on FCV023 proliferation. The addition of both inhibitors resulted in the reduced replication of FCV. Under conditions that do not affect cell viability, the inhibitory effect of 2-DG on FCV is more pronounced compared to Oxamate. This may be due to the fact that glucose-6-phosphate is the initial substrate for multiple metabolic pathways in central carbon metabolism. The addition of 2-DG inhibits the production of glucose-6-phosphate, thereby affecting several metabolic pathways, including glycolysis and the PPP, leading to a more potent inhibitory effect.</p><p>Recent studies on noroviruses in the Caliciviridae family have shown that the replication of mouse norovirus (MNV) is inseparable from glycolysis and glutamine metabolism, and blocking glycolysis and glutamine metabolism leads to a reduction in the synthesis of non-structural proteins and viral RNA in MNV [<xref rid="B24-vetsci-12-00138" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00138" ref-type="bibr">25</xref>]. Similarly, we found the same phenomenon in feline calicivirus (FCV), where the proliferation of FCV depends on unobstructed glycolysis. Recent research indicates that lactate produced by glycolysis can interact with mitochondrial antiviral protein (MAVS), thereby reducing the interaction between MAVS and RIG-I, inhibiting the production of IFN and thus interfering with the cell&#x02019;s antiviral response [<xref rid="B27-vetsci-12-00138" ref-type="bibr">27</xref>,<xref rid="B28-vetsci-12-00138" ref-type="bibr">28</xref>,<xref rid="B29-vetsci-12-00138" ref-type="bibr">29</xref>,<xref rid="B30-vetsci-12-00138" ref-type="bibr">30</xref>]. In FCV-infected CRFK cells, the upregulation of lactate dehydrogenase activity gene expression and the increase in the lactate content suggest that the accumulation of lactate induced by FCV infection may also play an important role in immune evasion, which may be the reason for the limited proliferation of FCV023 due to the inhibition of glycolysis.</p><p>During the analysis of central carbon metabolism-related metabolites in CRFK cells infected with FCV, it was found that FCV infection induced a remodeling of central carbon metabolism. Numerous studies have indicated that after viral infection, glutamine metabolism is enhanced to maintain cellular energy supply, and a similar phenomenon was observed in FCV-infected cells. The blockade of both the pentose phosphate pathway (PPP) and glutamine metabolism significantly inhibits the proliferation of FCV. We believe that glucose is predominantly directed towards the PPP in FCV023-infected cells to generate nucleotides, which are then utilized for the synthesis of the viral genome. Meanwhile, glutamine serves as an alternative energy substrate, producing &#x003b1;-ketoglutarate (&#x003b1;-KG) to replenish the TCA cycle [<xref rid="B31-vetsci-12-00138" ref-type="bibr">31</xref>,<xref rid="B32-vetsci-12-00138" ref-type="bibr">32</xref>], thus maintaining cellular energy homeostasis. Glutamine and glucose hold a special metabolic position in FCV-infected CRFK cells, and their roles are yet to be further investigated.</p><p>This study confirms that FCV infection remodels cellular central carbon metabolism, with optimal FCV replication being dependent on unimpeded glycolysis, PPP, and glutamine metabolism. The inhibition of these metabolic pathways can significantly suppress FCV replication and the production of infectious viral particles. Therefore, the development of targeted drugs against these metabolic pathways may be a feasible direction for the development of specific drugs against FCV, which is of positive significance for the prevention and treatment of FCV. The experimental results also indicate that the metabolism of carbon and nitrogen sources in cells is closely related to FCV infection and pathogenesis; hence, a further assessment of the impact of glucose and glutamine deprivation experiments on FCV proliferation is necessary.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00138"><title>5. Conclusions</title><p>In conclusion, our study elucidates that FCV infection hijacks the central carbon metabolism of CRFK cells to ensure its replication. The infection alters the host cell&#x02019;s metabolism of glucose and glutamine to enhance viral proliferation. The integrity of glycolysis, PPP, and glutamine metabolis m are key facilitators of FCV infection, and their inhibition significantly reduces FCV replication, demonstrating potent antiviral efficacy against FCV. This highlights the critical role of central carbon metabolism in FCV infection. Our research indicates that central carbon metabolism is a crucial link in FCV infection and represents a feasible therapeutic approach while also providing a new direction for the development of anti-FCV drugs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00138"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020138/s1">https://www.mdpi.com/article/10.3390/vetsci12020138/s1</uri>, Figure S1: Original image of <xref rid="vetsci-12-00138-f001" ref-type="fig">Figure 1</xref>C; Figure S2: Original image of <xref rid="vetsci-12-00138-f003" ref-type="fig">Figure 3</xref>G.; Figure S3:Original image of <xref rid="vetsci-12-00138-f004" ref-type="fig">Figure 4</xref>F.; Figure S4: Original image of <xref rid="vetsci-12-00138-f005" ref-type="fig">Figure 5</xref>F.</p><supplementary-material id="vetsci-12-00138-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00138-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>G.Z. and H.Z. were responsible for the experimental design, operation, data analysis and processing, and manuscript writing.; X.X. and C.Z. were responsible for completing the experimental validation; X.Y. and J.C. were responsible for the consulting and arrangement of the literature and participated in the isolation and purification of the strain; L.J., Y.L. and Y.H. conducted the proofreading and revision of the manuscript; X.Z. and J.Z. were responsible for funding acquisition. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The nucleotide sequence of FCV023 (PP112969) has been uploaded to the GenBank, and the nucleotide information will be publicly available on 1 February 2025. The data that support the findings of this study are available upon request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Yuanlong He is an employee of Shandong Huanong Biopharmaceutical Co., Ltd. The remaining authors have no conflicts of interest to declare.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00138"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hofmann-Lehmann</surname><given-names>R.</given-names></name>
<name><surname>Hosie</surname><given-names>M.J.</given-names></name>
<name><surname>Hartmann</surname><given-names>K.</given-names></name>
<name><surname>Egberink</surname><given-names>H.</given-names></name>
<name><surname>Truyen</surname><given-names>U.</given-names></name>
<name><surname>Tasker</surname><given-names>S.</given-names></name>
<name><surname>Bel&#x000e1;k</surname><given-names>S.</given-names></name>
<name><surname>Boucraut-Baralon</surname><given-names>C.</given-names></name>
<name><surname>Frymus</surname><given-names>T.</given-names></name>
<name><surname>Lloret</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Calicivirus Infection in Cats</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>937</elocation-id><pub-id pub-id-type="doi">10.3390/v14050937</pub-id><pub-id pub-id-type="pmid">35632680</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00138"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pesavento</surname><given-names>P.A.</given-names></name>
<name><surname>Chang</surname><given-names>K.O.</given-names></name>
<name><surname>Parker</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Molecular virology of feline calicivirus</article-title><source>Vet. Clin. N. Am. Small Anim. Pract.</source><year>2008</year><volume>38</volume><fpage>775</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2008.03.002</pub-id><pub-id pub-id-type="pmid">18501277</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00138"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radford</surname><given-names>A.D.</given-names></name>
<name><surname>Coyne</surname><given-names>K.P.</given-names></name>
<name><surname>Dawson</surname><given-names>S.</given-names></name>
<name><surname>Porter</surname><given-names>C.J.</given-names></name>
<name><surname>Gaskell</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Feline calicivirus</article-title><source>Vet. Res.</source><year>2007</year><volume>38</volume><fpage>319</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1051/vetres:2006056</pub-id><pub-id pub-id-type="pmid">17296159</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00138"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lanave</surname><given-names>G.</given-names></name>
<name><surname>Buonavoglia</surname><given-names>A.</given-names></name>
<name><surname>Pellegrini</surname><given-names>F.</given-names></name>
<name><surname>Di Martino</surname><given-names>B.</given-names></name>
<name><surname>Di Profio</surname><given-names>F.</given-names></name>
<name><surname>Diakoudi</surname><given-names>G.</given-names></name>
<name><surname>Catella</surname><given-names>C.</given-names></name>
<name><surname>Omar</surname><given-names>A.H.</given-names></name>
<name><surname>Vasinioti</surname><given-names>V.I.</given-names></name>
<name><surname>Cardone</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>An Outbreak of Limping Syndrome Associated with Feline Calicivirus</article-title><source>Anim. Open Access J. MDPI</source><year>2023</year><volume>13</volume><elocation-id>1778</elocation-id><pub-id pub-id-type="doi">10.3390/ani13111778</pub-id></element-citation></ref><ref id="B5-vetsci-12-00138"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baratta</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Virus-mediated hijack of one-carbon metabolism</article-title><source>Nat. Rev. Cancer</source><year>2019</year><volume>19</volume><fpage>486</fpage><pub-id pub-id-type="doi">10.1038/s41568-019-0190-0</pub-id><pub-id pub-id-type="pmid">31388126</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00138"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name>
<name><surname>Gong</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Icariin, Formononetin and Caffeic Acid Phenethyl Ester Inhibit Feline Calicivirus Replication In Vitro</article-title><source>Arch. Virol.</source><year>2021</year><volume>166</volume><fpage>2443</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1007/s00705-021-05107-w</pub-id><pub-id pub-id-type="pmid">34173062</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00138"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodwin</surname><given-names>C.M.</given-names></name>
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Munger</surname><given-names>J.</given-names></name>
</person-group><article-title>Stealing the Keys to the Kitchen: Viral Manipulation of the Host Cell Metabolic Network</article-title><source>Trends Microbiol.</source><year>2015</year><volume>23</volume><fpage>789</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2015.08.007</pub-id><pub-id pub-id-type="pmid">26439298</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00138"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Girdhar</surname><given-names>K.</given-names></name>
<name><surname>Powis</surname><given-names>A.</given-names></name>
<name><surname>Raisingani</surname><given-names>A.</given-names></name>
<name><surname>Chrudinov&#x000e1;</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>R.</given-names></name>
<name><surname>Tran</surname><given-names>T.</given-names></name>
<name><surname>Sevgi</surname><given-names>K.</given-names></name>
<name><surname>Dogus Dogru</surname><given-names>Y.</given-names></name>
<name><surname>Altindis</surname><given-names>E.</given-names></name>
</person-group><article-title>Viruses and Metabolism: The Effects of Viral Infections and Viral Insulins on Host Metabolism</article-title><source>Annu. Rev. Virol.</source><year>2021</year><volume>8</volume><fpage>373</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-091919-102416</pub-id><pub-id pub-id-type="pmid">34586876</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00138"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Deng</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Cellular metabolism hijacked by viruses for immunoevasion: Potential antiviral targets</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1228811</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1228811</pub-id><pub-id pub-id-type="pmid">37559723</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00138"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>K.</given-names></name>
<name><surname>Martin-Sancho</surname><given-names>L.</given-names></name>
<name><surname>Pal</surname><given-names>L.R.</given-names></name>
<name><surname>Pu</surname><given-names>Y.</given-names></name>
<name><surname>Riva</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>X.</given-names></name>
<name><surname>Sinha</surname><given-names>S.</given-names></name>
<name><surname>Nair</surname><given-names>N.U.</given-names></name>
<name><surname>Chanda</surname><given-names>S.K.</given-names></name>
<name><surname>Ruppin</surname><given-names>E.</given-names></name>
</person-group><article-title>Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets</article-title><source>Mol. Syst. Biol.</source><year>2021</year><volume>17</volume><elocation-id>e10260</elocation-id><pub-id pub-id-type="doi">10.15252/msb.202110260</pub-id><pub-id pub-id-type="pmid">34709707</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00138"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sambrook</surname><given-names>J.</given-names></name>
<name><surname>Russell</surname><given-names>D.W.</given-names></name>
</person-group><article-title>SDS-Polyacrylamide Gel Electrophoresis of Proteins</article-title><source>CSH Protoc.</source><year>2006</year><volume>2006</volume><fpage>pdb-prot4540</fpage><pub-id pub-id-type="doi">10.1101/pdb.prot4540</pub-id></element-citation></ref><ref id="B12-vetsci-12-00138"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Xue</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Zhen</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhan</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>China-origin G1 group isolate FPV072 exhibits higher infectivity and pathogenicity than G2 group isolate FPV027</article-title><source>Front. Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>1328244</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2024.1328244</pub-id><pub-id pub-id-type="pmid">38288138</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00138"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>G.</given-names></name>
<name><surname>Shi</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Guo</surname><given-names>Q.</given-names></name>
<name><surname>Han</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Majorbio Cloud: A one-stop, comprehensive bioinformatic platform for multiomics analyses</article-title><source>iMeta</source><year>2022</year><volume>1</volume><fpage>e12</fpage><pub-id pub-id-type="doi">10.1002/imt2.12</pub-id><pub-id pub-id-type="pmid">38868573</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00138"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>J.J.</given-names></name>
<name><surname>Guo</surname><given-names>L.Y.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Di</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Molecular link between glucose and glutamine consumption in cancer cells mediated by CtBP and SIRT4</article-title><source>Oncogenesis</source><year>2018</year><volume>7</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1038/s41389-018-0036-8</pub-id><pub-id pub-id-type="pmid">29540733</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00138"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>A.</given-names></name>
<name><surname>Roy</surname><given-names>A.C.</given-names></name>
<name><surname>Priya</surname><given-names>K.</given-names></name>
<name><surname>Meena</surname><given-names>R.</given-names></name>
<name><surname>Ghosh</surname><given-names>I.</given-names></name>
</person-group><article-title>Effect of differential deprivation of nutrients on cellular proliferation, oxidative stress, mitochondrial function, and cell migration in MDA-MB-231, HepG2, and HeLa cells</article-title><source>3 Biotech</source><year>2023</year><volume>13</volume><elocation-id>339</elocation-id><pub-id pub-id-type="doi">10.1007/s13205-023-03759-w</pub-id></element-citation></ref><ref id="B16-vetsci-12-00138"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howard-Varona</surname><given-names>C.</given-names></name>
<name><surname>Lindback</surname><given-names>M.M.</given-names></name>
<name><surname>Bastien</surname><given-names>G.E.</given-names></name>
<name><surname>Solonenko</surname><given-names>N.</given-names></name>
<name><surname>Zayed</surname><given-names>A.A.</given-names></name>
<name><surname>Jang</surname><given-names>H.</given-names></name>
<name><surname>Andreopoulos</surname><given-names>B.</given-names></name>
<name><surname>Brewer</surname><given-names>H.M.</given-names></name>
<name><surname>Glavina Del Rio</surname><given-names>T.</given-names></name>
<name><surname>Adkins</surname><given-names>J.N.</given-names></name>
<etal/>
</person-group><article-title>Phage-specific metabolic reprogramming of virocells</article-title><source>ISME J.</source><year>2020</year><volume>14</volume><fpage>881</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1038/s41396-019-0580-z</pub-id><pub-id pub-id-type="pmid">31896786</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00138"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Clippinger</surname><given-names>A.J.</given-names></name>
<name><surname>Alwine</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Viral effects on metabolism: Changes in glucose and glutamine utilization during human cytomegalovirus infection</article-title><source>Trends Microbiol.</source><year>2011</year><volume>19</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2011.04.002</pub-id><pub-id pub-id-type="pmid">21570293</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00138"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dekhne</surname><given-names>A.S.</given-names></name>
<name><surname>Hou</surname><given-names>Z.</given-names></name>
<name><surname>Gangjee</surname><given-names>A.</given-names></name>
<name><surname>Matherly</surname><given-names>L.H.</given-names></name>
</person-group><article-title>Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer</article-title><source>Mol. Cancer Ther.</source><year>2020</year><volume>19</volume><fpage>2245</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0423</pub-id><pub-id pub-id-type="pmid">32879053</pub-id>
</element-citation></ref><ref id="B19-vetsci-12-00138"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>J.</given-names></name>
<name><surname>Byun</surname><given-names>J.K.</given-names></name>
<name><surname>Choi</surname><given-names>Y.K.</given-names></name>
<name><surname>Park</surname><given-names>K.G.</given-names></name>
</person-group><article-title>Targeting glutamine metabolism as a therapeutic strategy for cancer</article-title><source>Exp. Mol. Med.</source><year>2023</year><volume>55</volume><fpage>706</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1038/s12276-023-00971-9</pub-id><pub-id pub-id-type="pmid">37009798</pub-id>
</element-citation></ref><ref id="B20-vetsci-12-00138"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Zeng</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Tu</surname><given-names>J.</given-names></name>
<name><surname>Nephew</surname><given-names>K.P.</given-names></name>
<name><surname>Long</surname><given-names>X.</given-names></name>
</person-group><article-title>Glutamine metabolism in breast cancer and possible therapeutic targets</article-title><source>Biochem. Pharmacol.</source><year>2023</year><volume>210</volume><elocation-id>115464</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115464</pub-id><pub-id pub-id-type="pmid">36849062</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00138"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amoedo</surname><given-names>N.D.</given-names></name>
<name><surname>Obre</surname><given-names>E.</given-names></name>
<name><surname>Rossignol</surname><given-names>R.</given-names></name>
</person-group><article-title>Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy</article-title><source>Biochim. Biophys. Acta. Bioenerg.</source><year>2017</year><volume>1858</volume><fpage>674</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2017.02.005</pub-id><pub-id pub-id-type="pmid">28213330</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00138"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>S.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Yao</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
</person-group><article-title>Small molecule metabolites: Discovery of biomarkers and therapeutic targets</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>132</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01399-3</pub-id><pub-id pub-id-type="pmid">36941259</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00138"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>C.H.</given-names></name>
<name><surname>Ivanisevic</surname><given-names>J.</given-names></name>
<name><surname>Siuzdak</surname><given-names>G.</given-names></name>
</person-group><article-title>Metabolomics: Beyond biomarkers and towards mechanisms</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2016</year><volume>17</volume><fpage>451</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.25</pub-id><pub-id pub-id-type="pmid">26979502</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00138"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hafner</surname><given-names>A.</given-names></name>
<name><surname>Meurs</surname><given-names>N.</given-names></name>
<name><surname>Garner</surname><given-names>A.</given-names></name>
<name><surname>Azar</surname><given-names>E.</given-names></name>
<name><surname>Kannan</surname><given-names>A.</given-names></name>
<name><surname>Passalacqua</surname><given-names>K.D.</given-names></name>
<name><surname>Nagrath</surname><given-names>D.</given-names></name>
<name><surname>Wobus</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Norovirus NS1/2 protein increases glutaminolysis for efficient viral replication</article-title><source>PLoS Pathog.</source><year>2024</year><volume>20</volume><elocation-id>e1011909</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011909</pub-id><pub-id pub-id-type="pmid">38976719</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00138"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Passalacqua</surname><given-names>K.D.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Goodfellow</surname><given-names>I.</given-names></name>
<name><surname>Kolawole</surname><given-names>A.O.</given-names></name>
<name><surname>Arche</surname><given-names>J.R.</given-names></name>
<name><surname>Maddox</surname><given-names>R.J.</given-names></name>
<name><surname>Carnahan</surname><given-names>K.E.</given-names></name>
<name><surname>O&#x02019;Riordan</surname><given-names>M.X.D.</given-names></name>
<name><surname>Wobus</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Glycolysis Is an Intrinsic Factor for Optimal Replication of a Norovirus</article-title><source>mBio</source><year>2019</year><volume>10</volume><fpage>e02175-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.02175-18</pub-id><pub-id pub-id-type="pmid">30862747</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00138"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>G.</given-names></name>
<name><surname>Duan</surname><given-names>C.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Xiao</surname><given-names>S.</given-names></name>
</person-group><article-title>Porcine reproductive and respiratory syndrome virus infection manipulates central carbon metabolism</article-title><source>Vet. Microbiol.</source><year>2023</year><volume>279</volume><elocation-id>109674</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2023.109674</pub-id><pub-id pub-id-type="pmid">36739813</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00138"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Xu</surname><given-names>Z.G.</given-names></name>
<name><surname>Tu</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>F.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS</article-title><source>Cell</source><year>2019</year><volume>178</volume><fpage>176</fpage><lpage>189.e115</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.003</pub-id><pub-id pub-id-type="pmid">31155231</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00138"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Qi</surname><given-names>W.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Xie</surname><given-names>Z.</given-names></name>
<name><surname>Jia</surname><given-names>W.</given-names></name>
<name><surname>Ning</surname><given-names>Z.</given-names></name>
</person-group><article-title>Senecavirus A-induced glycolysis facilitates virus replication by promoting lactate production that attenuates the interaction between MAVS and RIG-I</article-title><source>PLoS Pathog.</source><year>2023</year><volume>19</volume><elocation-id>e1011371</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011371</pub-id><pub-id pub-id-type="pmid">37126525</pub-id>
</element-citation></ref><ref id="B29-vetsci-12-00138"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Xue</surname><given-names>Z.</given-names></name>
<name><surname>Cao</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>H.</given-names></name>
</person-group><article-title>African Swine Fever Virus Regulates Host Energy and Amino Acid Metabolism To Promote Viral Replication</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0191921</fpage><pub-id pub-id-type="doi">10.1128/jvi.01919-21</pub-id><pub-id pub-id-type="pmid">34908441</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00138"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>Q.Q.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Nie</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
<name><surname>Deng</surname><given-names>F.</given-names></name>
<name><surname>Cheng</surname><given-names>Z.</given-names></name>
<name><surname>Zuo</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Cai</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>MAVS integrates glucose metabolism and RIG-I-like receptor signaling</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>5343</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41028-9</pub-id><pub-id pub-id-type="pmid">37660168</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00138"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stincone</surname><given-names>A.</given-names></name>
<name><surname>Prigione</surname><given-names>A.</given-names></name>
<name><surname>Cramer</surname><given-names>T.</given-names></name>
<name><surname>Wamelink</surname><given-names>M.M.</given-names></name>
<name><surname>Campbell</surname><given-names>K.</given-names></name>
<name><surname>Cheung</surname><given-names>E.</given-names></name>
<name><surname>Olin-Sandoval</surname><given-names>V.</given-names></name>
<name><surname>Gr&#x000fc;ning</surname><given-names>N.M.</given-names></name>
<name><surname>Kr&#x000fc;ger</surname><given-names>A.</given-names></name>
<name><surname>Tauqeer Alam</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway</article-title><source>Biol. Rev. Camb. Philos. Soc.</source><year>2015</year><volume>90</volume><fpage>927</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1111/brv.12140</pub-id><pub-id pub-id-type="pmid">25243985</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00138"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Hao</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Z.X.</given-names></name>
</person-group><article-title>Human papillomavirus-16 E6 activates the pentose phosphate pathway to promote cervical cancer cell proliferation by inhibiting G6PD lactylation</article-title><source>Redox Biol.</source><year>2024</year><volume>71</volume><elocation-id>103108</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2024.103108</pub-id><pub-id pub-id-type="pmid">38457903</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00138-f001"><label>Figure 1</label><caption><p>Identification of FCV in CRFK cells. (<bold>A</bold>) Cytopathic effect (CPE) of CRFK cells infected with FCV. (<bold>B</bold>) Immunofluorescence detection results 24&#x02009;h after inoculation. Scale bar =&#x02009; 275 &#x003bc;m. (<bold>C</bold>) Western blot analysis of total cell lysates from virus-infected cells using anti-FCV VP1 polyclonal antibodies. (<bold>D</bold>) Electron micrograph of FCV virions (arrow heads) in cell culture media of infected CRFK cells. Scale bar = 100 nm. (<bold>E</bold>) One-step growth curve analysis of CRFK cells infected with FCV023 strains over 36&#x02009;h; measurement at each time point was conducted in triplicate, and each experiment was set with three parallel groups. Average value was taken as TCID50 of virus. (<xref rid="app1-vetsci-12-00138" ref-type="app">Figure S1</xref>).</p></caption><graphic xlink:href="vetsci-12-00138-g001" position="float"/></fig><fig position="float" id="vetsci-12-00138-f002"><label>Figure 2</label><caption><p>FCV023 infection remodels the central carbon metabolism in CRFK cells. The abundance changes in major intermediate metabolites in the central carbon metabolism of CRFK cells during FCV023 infection.</p></caption><graphic xlink:href="vetsci-12-00138-g002" position="float"/></fig><fig position="float" id="vetsci-12-00138-f003"><label>Figure 3</label><caption><p>The inhibition of glycolysis inhibits the replication of FCV. (<bold>A</bold>) A schematic diagram of the functional targets of glycolytic pathway inhibitor drugs (2&#x02212;DG, Sodium Oxamate) used in this study. (<bold>B</bold>) The impacts of different final concentrations of inhibitory drugs on the viability of CRFK cells after 8 h of treatment. (<bold>C</bold>,<bold>D</bold>) FCV023 infects CRFK cells at an MOI of 1 and is incubated in the presence or absence of glycolytic inhibitors, with viral titers being determined after 8 h. (<bold>E</bold>,<bold>F</bold>) FCV023 infects CRFK cells at an MOI of 1, and the intracellular mRNA levels of the FCV VP1 gene are analyzed by q&#x02212;PCR after incubation in the presence or absence of glycolytic inhibitors for 8 h post-infection. (<bold>G</bold>,<bold>H</bold>) FCV023 infects CRFK cells at an MOI of 1 and is incubated in the presence or absence of glycolytic inhibitors, with the expression of FCV VP1 protein being analyzed by Western blotting after 8 h of infection. <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered as statistically significant, * <italic toggle="yes">p</italic> &#x0003c; 0.05, *** <italic toggle="yes">p</italic> &#x0003c; 0.01. (<xref rid="app1-vetsci-12-00138" ref-type="app">Figure S2</xref>).</p></caption><graphic xlink:href="vetsci-12-00138-g003" position="float"/></fig><fig position="float" id="vetsci-12-00138-f004"><label>Figure 4</label><caption><p>(<bold>A</bold>) A schematic diagram of the target sites of the PPP inhibitor 6-AN. (<bold>B</bold>) Changes in the viability of CRFK cells after treatment with 6-AN for 8 h. (<bold>C</bold>) The impact of 6-AN treatment on viral genome replication in FCV-infected CRFK cells (MOI = 1). (<bold>D</bold>) The impact of 6-AN treatment on viral titers in cells infected with FCV023 (MOI = 1). (<bold>E</bold>,<bold>F</bold>) FCV023 infects CRFK cells at an MOI of 1 and is incubated in the presence or absence of 6-AN, with the expression of FCV VP1 protein being analyzed by Western blotting after 8 h of infection. <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered as statistically significant, * <italic toggle="yes">p</italic> &#x0003c; 0.05, *** <italic toggle="yes">p</italic> &#x0003c; 0.01. (<xref rid="app1-vetsci-12-00138" ref-type="app">Figure S3</xref>).</p></caption><graphic xlink:href="vetsci-12-00138-g004" position="float"/></fig><fig position="float" id="vetsci-12-00138-f005"><label>Figure 5</label><caption><p>(<bold>A</bold>) A schematic diagram of the mechanism by which CB-839 inhibits glutamine metabolism. (<bold>B</bold>) Fluctuations in CRFK cell viability (incubation with CB-839 for 8 h). (<bold>C</bold>,<bold>D</bold>) The impact of treatment with 0.2 mM of CB-839 on viral genome replication and the release of infectious viral particles. (<bold>E</bold>,<bold>F</bold>) The effect of glutamine metabolism inhibition on the expression of FCV capsid proteins. <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered as statistically significant, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.01. (<xref rid="app1-vetsci-12-00138" ref-type="app">Figure S4</xref>).</p></caption><graphic xlink:href="vetsci-12-00138-g005" position="float"/></fig><table-wrap position="float" id="vetsci-12-00138-t001"><object-id pub-id-type="pii">vetsci-12-00138-t001_Table 1</object-id><label>Table 1</label><caption><p>The PCR primers used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence (5&#x02032; to 3&#x02032;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Size</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">FCV-F</td><td align="center" valign="middle" rowspan="1" colspan="1">ATACCCGCCAATCAACATGT</td><td rowspan="2" align="center" valign="middle" colspan="1">84 bp</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FCV-R</td><td align="center" valign="middle" rowspan="1" colspan="1">AGTCAATGTCAGGTGTCGGC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Beta-actin-F</td><td align="center" valign="middle" rowspan="1" colspan="1">AAAGTCCAGGGCCACATAGC</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">400 bp</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beta-actin-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGGACTGCTATGTGGGGGAT</td></tr></tbody></table><table-wrap-foot><fn><p>Note: F is forward primer, R is reverse primer.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-12-00138-t002"><object-id pub-id-type="pii">vetsci-12-00138-t002_Table 2</object-id><label>Table 2</label><caption><p>The qPCR reaction protocol.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage 1</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-denaturation</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rep:1</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95 &#x000b0;C</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5 min</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Stage 2</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cycling reaction</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rep:40</td><td align="center" valign="middle" rowspan="1" colspan="1">95 &#x000b0;C</td><td align="center" valign="middle" rowspan="1" colspan="1">10 s</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 s</td></tr></tbody></table></table-wrap></floats-group></article>